Bernstein analyst Oswald Clint upgrades Eni (NYSE:E) from Market Perform to Outperform.
Regulatory Hurdle For Innate Pharma’s Blood Cancer Studies
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).
